TGF β for Immuno-Oncology Drug Development

Expression of a TGF-β Inhibitor from an Oncolytic Vaccinia Virus

From Cell Signaling to the Tumor Microenvironment, Exploit TGF-β’s Role in IO to Harness a Clinically Relevant, Safe & Efficacious Therapeutic.

SPEAKER : Steve Thorne

13TH INTERNATIONAL ONCOLYTIC VIRUS CONFERENCEOncolytic Viruses Symposium

The VET Platform: Re-targeting Oncolytic Vaccinia Virus to Tumors through Expression of Chemokine Receptors

SPEAKER : Steve Thorne

Oncolytic Virotherapy Summit

Boston | MA

The Design of Oncolytic Viral Therapies for Intravenous Delivery

SPEAKER : Steve Thorne

Oncolytic Viruses Symposium

Oxford Global

A Dual Pipeline Strategy Bringing Potent Vaccinia-Based Oncolytic Immunotherapies to the Clinic

SPEAKER : Steve Thorne